Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more
Market Cap & Net Worth: Amphastar P (AMPH)
Amphastar P (NASDAQ:AMPH) has a market capitalization of $885.17 Million ($885.17 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8959 globally and #4414 in its home market, demonstrating a 1.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amphastar P's stock price $19.51 by its total outstanding shares 45370171 (45.37 Million).
Amphastar P Market Cap History: 2015 to 2026
Amphastar P's market capitalization history from 2015 to 2026. Data shows growth from $645.62 Million to $885.17 Million (4.59% CAGR).
Index Memberships
Amphastar P is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.03% | #251 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #960 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.04% | #151 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.36 Trillion | 0.08% | #485 of 602 |
Weight: Amphastar P's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amphastar P Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amphastar P's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.69x
Amphastar P's market cap is 1.69 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
12.39x
Amphastar P's market cap is 12.39 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $835.72 Million | $255.16 Million | $10.53 Million | 3.28x | 79.35x |
| 2017 | $872.92 Million | $240.18 Million | $4.51 Million | 3.63x | 193.64x |
| 2018 | $902.87 Million | $294.67 Million | -$5.74 Million | 3.06x | N/A |
| 2019 | $875.19 Million | $322.36 Million | $48.94 Million | 2.71x | 17.88x |
| 2020 | $912.39 Million | $349.85 Million | $1.40 Million | 2.61x | 650.32x |
| 2021 | $1.06 Billion | $437.77 Million | $62.12 Million | 2.41x | 17.01x |
| 2022 | $1.27 Billion | $498.99 Million | $91.39 Million | 2.55x | 13.91x |
| 2023 | $2.81 Billion | $644.39 Million | $137.54 Million | 4.35x | 20.40x |
| 2024 | $1.68 Billion | $731.97 Million | $159.52 Million | 2.30x | 10.56x |
| 2025 | $1.22 Billion | $719.89 Million | $98.09 Million | 1.69x | 12.39x |
Competitor Companies of AMPH by Market Capitalization
Companies near Amphastar P in the global market cap rankings as of March 19, 2026.
Key companies related to Amphastar P by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Amphastar P Historical Marketcap From 2015 to 2026
Between 2015 and today, Amphastar P's market cap moved from $645.62 Million to $ 885.17 Million, with a yearly change of 4.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $885.17 Million | -27.15% |
| 2025 | $1.22 Billion | -27.88% |
| 2024 | $1.68 Billion | -39.97% |
| 2023 | $2.81 Billion | +120.74% |
| 2022 | $1.27 Billion | +20.31% |
| 2021 | $1.06 Billion | +15.81% |
| 2020 | $912.39 Million | +4.25% |
| 2019 | $875.19 Million | -3.07% |
| 2018 | $902.87 Million | +3.43% |
| 2017 | $872.92 Million | +4.45% |
| 2016 | $835.72 Million | +29.44% |
| 2015 | $645.62 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Amphastar P was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $885.17 Million USD |
| MoneyControl | $885.17 Million USD |
| MarketWatch | $885.17 Million USD |
| marketcap.company | $885.17 Million USD |
| Reuters | $885.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.